KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $355.9 million.

  • Royalty Pharma's Profit After Tax rose 644.89% to $355.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 116.97%. This contributed to the annual value of $1.3 billion for FY2025, which is 49.75% down from last year.
  • Royalty Pharma's Profit After Tax amounted to $355.9 million in Q4 2025, which was up 644.89% from $444.2 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Profit After Tax high stood at $806.8 million for Q2 2021, and its period low was -$610.0 million during Q4 2022.
  • For the 5-year period, Royalty Pharma's Profit After Tax averaged around $291.8 million, with its median value being $278.1 million (2021).
  • In the last 5 years, Royalty Pharma's Profit After Tax crashed by 123661.01% in 2022 and then soared by 897143.16% in 2025.
  • Royalty Pharma's Profit After Tax (Quarter) stood at $53.7 million in 2021, then tumbled by 1236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then plummeted by 53.41% to $334.4 million in 2024, then grew by 6.45% to $355.9 million in 2025.
  • Its Profit After Tax was $355.9 million in Q4 2025, compared to $444.2 million in Q3 2025 and $90.6 million in Q2 2025.